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Abstract: Background: Medication-related osteonecrosis of the jaw (MRONJ) can be a life changing
iatrogenic complication of antiresorptive and antiangiogenic drug therapy. It is most often associated
with high doses of these medications that are used to prevent skeletal-related events in patients
with cancer and bone pathologies. Unfortunately, managing MRONJ lesions has proven difficult
and remains a major challenge for clinicians. Due to the lack of efficacy in treating MRONJ by
surgical modalities (local debridement and free flap reconstruction), the nonsurgical management
of MRONJ is still advocated to aid healing or avoid disease progression. The aim of this systematic
review is to identify, analyse and understand the published evidence related to the success of oxygen
therapies such as ozone (OT) and hyperbaric oxygen (HBO) in treating MRONJ. Material and methods:
A multi-database (PubMed, MEDLINE, EMBASE, CINAHL and Cochrane CENTRAL) systematic
search was performed by three authors. The identified articles were independently assessed for their
risk of bias. Any type of study evaluating humans treated with antiresorptive and antiangiogenic
drugs were considered. The aim is primarily to evaluate the success of OT and HBO in resolving
MRONJ and secondarily to identify any improvements in quality of life (QoL), rate of complications,
time-to-event and severity of side effects related to these treatments. Results: In total, just 13 studies
were eligible for analysis. A pooled total of 313 patients (HBO group n = 82; OT group n = 231)
described in these studies have shown good tolerance for oxygen therapies. Complete resolution
of MRONJ was reported in 44.58% of OT patients but only 5.17% of the HBO group. Progression of
MRONJ was reported only in the HBO studies in 10.34% of cases (6 patients). The quality of evidence
was low or very low in all studies. This was due to limitations in how the studies were designed, run
and reported. Conclusions: Based on the limited data available, it is difficult to suggest OT is better or
worse than HBO or whether it is better than a placebo. As the level of evidence available is low, this
necessitates larger well-designed trials to justify these interventions for patients affected by MRONJ.
Appl. Sci. 2019, 9, 1026; doi:10.3390/app9051026 www.mdpi.com/journal/applsci
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1. Introduction
The term ‘medication-related osteonecrosis of the jaws’ (MRONJ) refers to a potentially serious
iatrogenic complication of treatment with medications, such as antiangiogenic or antiresorptive drugs.
These drug families are used primarily for the treatment of malignancies (e.g., multiple myeloma or
bone metastases) but also have important roles in the management of osteoporosis, Paget’s disease
and hypercalcemia. The bone targeting agents (BTAs) can reduce the risk of skeletal-related adverse
events to protect the skeleton in patients with primary or secondary bone pathology [1,2].
Since the first reports of bisphosphonate-related osteonecrosis of the jaw in 2003, an increasing
number of reports have been published showing similar clinical complications associated with
other drugs. New evidence has shown that along with bisphosphonates (BPs), other BTAs such
as denosumab also cause osteonecrosis of the jaw bones. In addition, monoclonal antibodies able to
bind and selectively inhibit vascular endothelial growth factor-A (VEGF-A), specifically mammalian
target of rapamycin (mTOR) inhibitors, can also cause similar lesions [3–5]. For this reason, the term
MRONJ was adopted in the 2014 position paper of the American Association of Oral and Maxillofacial
Surgeons (AAOMS) [3]. The medications currently reported to be associated with MRONJ are listed in
Table 1 (antiresorptive drugs) and Table 2 (antiangiogenic agents) [6,7].
The AAOMS position paper states that “patients may be considered to have MRONJ if all
the following characteristics are present: current or previous treatment with antiresorptive or
antiangiogenic agents; exposed bone or bone that can be probed through an intraoral or extraoral
fistula in the maxillofacial region that has persisted for longer than 8 weeks; and no history of radiation
therapy to the jaws or obvious metastatic disease to the jaws”. However, it is accepted that some
patients may present with non-specific symptoms and may not have evidence of exposed bone such
as those classified as Stage 0 by the AAOMS staging system [8]. The term ‘stage 0’ was first used by
Mawardi et al. to gather suspected MRONJ cases presenting with clinical and radiological signs of
disease other than intraoral bone exposure [9]. The AAOMS classification and staging system is based
entirely on the intraoral presentation, which they propose should also guide potential treatment. This
has been criticised in studies where it was highlighted that radiological findings are an important part
of the clinical picture necessary for accurate MRONJ staging (Tables 3 and 4) [6,8,10].
The major risk factor for the development of MRONJ is dento-alveolar surgery, with a history
of tooth extraction or oral surgery procedure (apicectomy or cystectomy) reported in 52% to 80% of
patients with MRONJ [11–13]. The overall risk of developing MRONJ after dento-alveolar surgery,
in patients on IV bisphosphonates ranges from 1.6% to 14.8% in comparison to 0.5% for patients taking
oral bisphosphonates [6].
To date, there is no current standard for the treatment of MRONJ associated with antiresorptive
or antiangiogenic drug therapy. Several treatment options have been described, with the earlier
stages of MRONJ reportedly responding well to conservative management such as topical or systemic
antibiotics, or limited bone debridement, although this still remains controversial [14,15].
Ozone therapy (OT) and hyperbaric oxygen therapy (HBO) have been reported as effective
adjunctive therapies in situations where normal bony wound healing is impaired, such as
osteoradionecrosis and chronic osteomyelitis of the jaw [16–18].
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Table 1. Antiresorptive drugs associated with medication-related osteonecrosis of the jaws (MRONJ). Btl: Bottle; IM: Intramuscular; IV: Intravenous; MM: Multiple
myeloma; PO: Orally; SC: Subcutaneous; SRE: Skeletal-related event; Tab: Tablet.
Pharmacologic Active
Ingredient Formulation Route of Administration Indication and Frequency
Alendronic acid (sodium salt) Tab 70 mgTab 10 mg PO
Treatment of postmenopausal osteoporosis (70 mg/week)
Treatment of osteoporosis in men (70 mg/week)
Treatment and prevention of osteoporosis induced by glucocorticoids (70 mg/week)
Alendronic acid +
cholecalciferol Tab 70 mg/5600 UI PO Treatment of postmenopausal osteoporosis in patients with unsupplemented vitamin D deficit (70 mg/week)
Ibandronic acid (monosodium
salt monohydrate)
Tab 50 mg
Btl 6 mg/6 mL
Tab 150 mg
Btl 3 mg/3 mL
PO
IV
PO
IV
Prevention of SREs in breast cancer patients with bone metastases (50 mg/day p.o. or 6 mg every 3–4 weeks iv.)
Treatment of hypercalcemia of malignancy
Treatment of postmenopausal osteoporosis in patients at high risk of fracture (150 mg/4 weeks p.o. or 3 mg
every 3 months iv.)
Neridronate acid (sodium salt) Btl 25 mg/2 mLBtl 100 mg/8 mL
IV/IM.
IV
Osteogenesis imperfecta (2 mg/kg/3 months)
Treatment of Paget’s disease (different schedules)
Risedronic acid Tab 35 mgTab 5 mg PO
Treatment of postmenopausal osteoporosis (35 mg weekly or 5 mg daily)
Treatment and prevention of osteoporosis induced by glucocorticoids (35 mg weekly or 5 mg daily)
Treatment of Paget’s disease
Zoledronic acid (monohydrate) Btl 4 mg/5 mLBtl 5 mg/100 mL
IV
IV
Prevention of SREs in cancer patients with bone metastases or MM (4 mg every 3–4 weeks). Treatment of
hypercalcemia of malignancy
Treatment of osteoporosis in postmenopausal women, in men at increased risk of fracture, including those with
a recent hip fracture from minor trauma (5 mg once per year)
Treatment of Paget’s disease
Denosumab Btl 120 mgBtl 60 mg
SC
SC
Prevention of SREs in cancer patients with bone metastases (120 mg every 4 weeks)
Treatment of hypercalcemia of malignancy.
Osteoporosis (60 mg sc. every 6 months)
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Table 2. Antiangiogenic drugs associated with MRONJ. IV: Intravenous; MM: Multiple myeloma; PO:
Orally; SC: Subcutaneous; Btl: Bottle; Tab: Tablet.
Pharmacologic
Active Ingredient Formulation
Route of
Administration Indication and Frequency
Bevacizumab Btl 400 mgBtl 100 mg IV
Metastatic breast cancer (10 mg/kg every
2 weeks or 15 mg/kg every 3 weeks);
colorectal cancer (5 mg/kg or 10 mg/kg
every 2 weeks); lung/ovarian cancer
(7.5 mg/kg or 15 mg/kg every 3 weeks);
renal cell cancer (10 mg/kg every 2 weeks);
glioblastoma (10 mg/kg every 2 weeks)
Sunitinib Tab 12.5 mg PO
Renal cell cancer, GISTs and
neuroendocrine tumours (50 mg/day for
4 weeks)
Sorafenib Tab 200 mg PO Renal cell cancer (800 mg/day)
Pazopanib Tab 200 mgTab 400 mg PO Renal cell cancer (200–800 mg/day)
Thalidomide Tab 50 mg PO Myeloma (400 mg/day for 6 weeks)
Lenalidomide Tab 5, 10, 15 and 25 mg PO Myeloma (tailored doses)
Everolimus Tab 5 and 10 mg PO Renal cell cancer, breast cancer (10 mgevery day)
Temsirolimus Btl 30 mg IV Renal cell cancer (25 mg every week)
Table 3. MRONJ staging from the American Association of Oral and Maxillofacial Surgeons (AAOMS)
position paper (2014) [6].
Stage MRONJ Clinical Findings
At risk category No apparent necrotic bone in patients who have been treated with eitheroral or IV bisphosphonates
Stage 0 No clinical evidence of necrotic bone, but non-specific clinical findings,radiographic changes and symptoms
Stage 1 Exposed and necrotic bone, or fistulae that probes to bone, in patientswho are asymptomatic and have no evidence of infection
Stage 2
Exposed and necrotic bone, or fistulae that probes to bone, associated
with infection as evidenced by pain and erythema in the region of the
exposed bone with or without purulent drainage
Stage 3
Exposed and necrotic bone or a fistula that probes to bone in patients
with pain, infection, and one or more of the following: exposed and
necrotic bone extending beyond the region of alveolar bone,(i.e., inferior
border and ramus in the mandible, maxillary sinus and zygoma in the
maxilla) resulting in pathologic fracture, extra-oral fistula, oral
antral/oral nasal communication or osteolysis extending to the inferior
border of the mandible of sinus floor
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Table 4. MRONJ staging (clinical and radiological findings) proposed by Campisi et al. 2011 [10].
Stage MRONJ Features
Stage 1
Focal ONJ
Clinical signs and symptoms: bone exposure, sudden dental mobility,
non-healing post-extraction socket, mucosal fistula, swelling, abscess
formation, trismus and gross mandible deformity hypoesthesia/paraesthesia
of the lips CT signs: increased bone density limited to the alveolar bone
region (trabecular thickening and focal osteosclerosis), with or without the
following signs: markedly thickened and sclerotic lamina dura, persisting
alveolar socket and cortical disruption
Stage 2
Diffuse ONJ
Clinical signs and symptoms: same as stage 1
CT signs: increased bone density extended to the basal bone (diffuse
osteosclerosis), with or without the following signs: prominence of the
inferior alveolar nerve canal, periosteal reaction, sinusitis, sequestra
formation and oro-antral fistula
Stage 3
Complicated ONJ
Same as stage 2, with one or more of the following:
Clinical signs and symptoms: extra-oral fistula, displaced mandibular stumps
and nasal leakage of fluids
CT signs: osteosclerosis of adjacent bones (zygoma and hard palate),
pathologic mandibular fracture and osteolysis extending to the sinus floor
HBO increases local concentrations of reactive nitrogen species (RNS) and reactive oxygen
species (ROS) by providing substrates (oxygen and L-arginine) for nitric oxide synthase, as well
as by the generation of superoxide [19,20]. ROS and RNS influence osteoclast (OC) differentiation and
activity and participate in the regulation of various aspects of bone metabolism [21–23]. Nitric oxide
(NO) is constitutively synthesised by both OCs and osteoblasts (OBs) and has contrasting biphasic
effects. At lower levels, NO decreases bone resorption and stimulates its turnover; whereas at higher
concentrations, NO promotes inflammatory processes and inhibits bone formation [24]. Indeed, ROS
stimulate the expression of receptor activator of nuclear factor kappa-B ligand (RANKL), changing
the RANKL/osteoprotegerin ratio and favouring OC differentiation, and avoiding osteopetrosis
in animal models [22,25]. Authors have also suggested that HBO-generated ROS could induce
suppression of OC activity and promote bone healing [21,23]. Recent research has shown that
HBO-generated ROS and RNS induce stem cell mobilisation, vasculogenesis, mitochondrial biogenesis
and preconditioning [26–29].
Ozone dissolves physically in biological water (physiological saline, plasma, lymph, urine).
All these reagents act as donor electrons and are oxidisable, and participate in the ozonation process
and the consequent formation of ROSs and lipid oxidation products (LOPs). These molecules
are responsible for the biochemical actions of ozone and function as biochemical regulators of
inflammation at distinct times and physiological concentrations [30,31]. Through interactions with
cellular components and depending on the concentration of ozone in the tissue, these molecules can
trigger biological effects that are either therapeutic or detrimental to health [30,31].
During normal metabolism, osteoclasts, platelets, lymphocytes, neutrophils, monocytes and
fibroblasts can induce the formation of ROS [32,33]. When in excess, these ROSs can trigger damage to
cellular constituents, extracellular components and affect the metabolism of the cells responsible for
extracellular matrix synthesis—fundamental in tissue repair—which leads to apoptosis and cellular
necrosis [34,35].
The aim of this review is to analyse all available evidence and evaluate the reported outcome of
oxygen therapy as treatment for patients affected by MRONJ.
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2. Material and Methods
This systematic review was performed according to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [36]. The following databases were interrogated:
PubMed, MEDLINE, EMBASE, CINAHL and the Cochrane Central Register of Controlled Trials
(CENTRAL). A three-stage screening approach was used to ensure precision and the quality of the
search. The screening of titles and abstracts was carried out independently by three authors (RS, RL
and SO) to eliminate any irrelevant material (i.e., reviews, animal studies, non-clinical studies and
studies that did not report patients undergoing oxygen therapy treatments). Disagreements were
resolved by discussion until a consensus was reached.
A data screening and abstraction form was used to:
(1) Verify the study eligibility derived from the inclusion/exclusion criteria.
(2) Carry out the methodological quality assessment.
(3) Extract data on study characteristics and outcomes for the included studies.
The authors of any studies eligible for inclusion in the review, unless without sufficient
information, were contacted directly (Figure 1).
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3. Criteria for Inclusion in this Review
3.1. Types of Studies
The types of studies included in the research strategy were published or unpublished randomised
controlled trials, case-controlled trials, case series, retrospective studies and case reports. Papers were
obtained from January 2003 to September 2018. Animal studies, reviews and those studies including
patients with a previous history of radiation therapy to the head and neck regions were excluded.
No language restrictions were imposed to the search.
3.2. Types of Participants
The review considered studies involving patients who developed MRONJ and subsequently
underwent OT and/or HBO treatment. No restriction of age, gender or ethnic origin was applied.
There was also no restriction on the minimum number of patients included in the studies.
3.3. Types of Interventions
Patients affected by MRONJ who underwent OT and/or HBO as either standalone or adjuvant
treatment were considered.
3.4. Objectives
The objectives was to assess the therapeutic effects of HBO and OT in patients exposed to
antiresorptive or antiangiogenic drugs and affected by MRONJ. Moreover, it was to assess the effects
of OT and HBO therapy as standalone or adjuvant treatments (either singly or in combination to other
treatments) in people with manifest MRONJ.
4. Types of Outcome Measures
â Primary outcomes
• Healing of MRONJ as indicated by one or more of the following indicators:
# Improvement in the clinical grade of the lesions according to the AAOMS staging of
MRONJ (Table 3).
# Wound healing (yes or no).
# Plain film radiological examination (improvement of sclerotic changes, mottling and
bone fragmentation, improvement of formed sequestrum or persistent extraction
sockets), computed tomography (CT) scan, magnetic resonance imaging (MRI)
(surface area of the bone disease, localisation, evidence of bone marrow disease),
positron emission tomography (PET)/CT imaging (decreased abnormal focal
uptake) [37].
# Healing of sinus tract or deep periodontal pockets.
• Rate of progression of MRONJ
â Secondary outcomes
• Quality of life (QoL).
• Time-to-event.
• Rate of complications and side effects of the intervention.
For the ‘complications’ outcome measure, interventions involving an interruption or delay of
antiresorptive or antiangiogenic treatments, or progression of the underlying disease (e.g., fracture in
osteoporosis or disease progression in cancer), were considered to be complications of the intervention.
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For QoL measures, we reported whether validated scales were used. Non-validated scales were
not excluded a priori. QoL had to have been measured at baseline and at least once during follow-up.
5. Data Extracted
Data extracted from the studies included number of patients; patient gender and age; predisposing
factors for and localisation of MRONJ; type of antiangiogenic or antiresorptive drugs and their
cumulative dose; clinical indications for the drug or combined therapy; type of intervention;
complications; follow up time; MRONJ evolution and MRONJ recurrence.
All selected papers were carefully read to identify author(s); year of publication; study design;
population and treatment characteristics.
In the case of missing information, we contacted the authors and allowed six weeks for a reply.
If the information was still missing, we then indicated the missing data as ‘Not Reported (NR)’ in the
text and tables.
6. Review Quality Assessment Data
Two review authors (RS, AL) appraised the risk of bias in the included study with the tool
recommended by the Cochrane Handbook for Systematic Reviews of Interventions as appropriate
for randomised control trials (RCTs) [38]. Moreover, the authors used the CARE Checklist for case
report and the Modified Delphi Checklist for the case series studies [39,40]. We referred instances of
disagreement in risk of bias assessments to one of the other members of the review team (SO) and
resolved them by discussion.
7. Results
A total of 13 articles were included in this review. Of these, 6 reported patients treated with HBO
and 7 articles included patients treated using OT. All the published data described patients treated
from 2006 to 2015. The types of articles included in this research were case series (n = 9), case reports
(n = 3) and RCTs (n = 1) [41–53]. Results were expressed as descriptive statistics because of significant
heterogeneity in the published data.
7.1. List of Excluded Studies
Currently the treatment of MRONJ is controversial, but many researchers agree that intravenous
drug administration or longer period of drug intake contribute to high risk of developing MRONJ [54–56].
We originally considered 22 studies to be potentially eligible for inclusion, but after inspection of
the full papers, 9 were excluded for not meeting the inclusion criteria for this review [57–65] (Table 5).
Table 5. List of excluded studies.
Authors Type ofIntervention
Number of
Patients Type of Drug Type of Study Outcome
Petrucci et al. 2007
[57] OT + Surgery 12 IV-BP Letter to editor
8 patients (75%) achieved
complete resolution of
ONJ, and 4 (25%) achieved
improvement with
persistence of lesion
Agrillo et al. 2007
[58]
OT prevention
strategy for dental
extraction
15 NR Case Series No development of ONJ
Yamazaki et al.
2010 [59] HBO 1 Oral BP Abstract
Improvement with
persistence of lesion
Karakinaris et al.
2013 [60]
HBO + Drug holiday
+ Surgery 25 Unclear Poster/Presentation All patients free from ONJ
Salcedo Gil et al.
2013 [61]
Retrospective
Comparative (HBO
group vs. No-HBO
group) as adjuvant
therapy
15 HBO Vs 15
No-HBO BP Poster/Presentation
Significant improvement
with persistence of lesion
and or stabilization
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Table 5. Cont.
Authors Type ofIntervention
Number of
Patients Type of Drug Type of Study Outcome
Zaslavskaya et al.
2013 [62]
OT + removal of
sequestrum 30 IV-BP Poster/Presentation All patients free from ONJ
Asaka 2014 [63] HBO + Minimalsurgery 8 NR Poster/Presentation
All patients presented
good clinical and
radiological result
Hamada 2014 [64] HBO + Surgery +stopping BP 3
IV-BP and Oral
BP Poster/Presentation All patients free from ONJ
Yahoo et al. 2018
[65] OT + Surgery 2
One on DZB
and one on
IV-BP
Poster Presentation All patients free from ONJ
7.2. HBO Study Analysis
In total just 6 articles were included in the analysis of HBO therapy comprising case reports
(n = 2), case series (n = 3) and RCTs (n = 1). All studies were published from 2006 to 2015. A total of
82 patients with a mean age 66.3, 45 female (54.88%) and 37 male (45.12%) cases, were treated using
different protocols of HBO therapy (Tables 6 and 7). None of the manuscripts reported patients treated
with antiangiogenic drugs.
Table 6. Studies included in the hyperbaric oxygen (HBO) analysis, including number of patients
treated and evidence level. Case series (CS); case report (CR); randomised control clinical
trial (RCT); Levels of Evidence for Prognostic Studies Adapted from the American Society of
Plastic Surgeons (https://www.plasticsurgery.org/Documents/medical-professionals/health-policy/
evidence-practice/ASPS-Rating-Scale-March-2011.pdf).
Author(s) Type of Study Total Number of Patients Level of Evidence
Shimura et al. 2006 [41] CR 1 Level 5
Lee et al. 2007 [42] CS 2 Level 4
Freiberger et al. 2007 [43] CS 16 Level 4
Lee et al. 2011 [44] CS 13 Level 4
Freiberger et al. 2012 [45] RCT 49;(3 patients died at early stage of study) Level 2
Fatema et al. 2015 [46] CR 1 Level 5
The reported indications for antiresorptive drug treatment were multiple myeloma (37.80%),
osteoporosis (21.95%), breast cancer (18.29%), prostate cancer (4.88%), non-Hodgkin lymphoma (2.44%),
sarcoidosis (1.22%) and macroglobulinaemia (1.22%). In addition, a significant number of patients
were logged with no specific indication (n = 10, 12.20%) (Table 8).
The most common site for MRONJ was the mandible (18.29%) followed by the maxilla (3.65%).
In 2.43% of patients, MRONJ lesions were reported in both (Table 7). However, in 75.60% the MRONJ
site was not reported (NR). The drug most commonly responsible of MRONJ was Zoledronate (12.19%),
but only 33 patients out of 82 had this detail reported (40.24%).
HBO was most commonly used as a neoadjuvant and/or adjuvant therapy, followed by surgery
in 4 studies out of 6. In one study the HBO therapy was given as standalone treatment (Table 9).
The patients were followed for a period of time ranging from 1 to 32 months. At the end of the
follow up, MRONJ was seen as completely resolved in 5.17% of the cases (n = 3), while the majority
(48.27%) of the patients (n = 28) were reported to have some benefit due to stability or improvement of
the disease presentation. In just 10.34% of patients (n = 6), the disease progressed, but for 13 patients
(22.41%), data were not available (Table 10).
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Table 7. HBO Preoperative epidemiologic analysis (age, sex, predisposing factors and site of the necrosis involved). M: male; F: female; not reported (NR), Standard of
Care (StC).
Study Patient Numbers Age/Sex Triggering Cause Site of the Necrosis Involved
Shimura et al. 2006 [41] 1 60 M Spontaneous 1 in mandible
Lee et al. 2007 [42] 2 84 F76 M
Dental implant;
Bone graft surgery
1 in the maxilla;
1 in the mandible
Freiberger et al. 2007 [43] 16
63 F, 69 F, 57 M, 53 M, 70 M, 45 F,
62 M, 59 M, 78 F, 56 M, 52 M, 52 F,
72 M, 77 M, 43 F, 63 M (total
patients 6 female and 10 male)
NR
12 in the mandible;
2 in the maxilla;
2 in both maxilla and mandible
Lee et al. 2011 [44] 13
62 M, 87 M, 54 F, 81 F, 68 M, 75 F,
70 F, 70 F, 57 F, 83 F, 76 M, 74 F, 62 F
(total patients 4 male and 9 female)
NR NR
Freiberger et al. 2012 [45]
27 (StC-group), 22 (HBO-StC
group). Total Patients 46
3 early dead during study (2 on
the StC StC-group and 1 on the
HBO-StC group).
(mean age, 66 years; 57% female) NR NR
Fatema et al. 2015 [46] 1 80 F Dental extraction 1 in the mandible
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Table 8. HBO preoperative pharmacological analysis: type of drugs, indication for drug therapy, and time of drug exposure; Minodronate (MI); Zoledronate acid
(ZOL); Pamidornate (PAM); Bisphosphonate (BP); Alendronate (ALD); Risedronate (RES); Ibadronate (IBA); Osteoporosis (OP); Multiple Myeloma (MM); Breast
Cancer (BC); Sarcoidosis (SC); Prostate Cancer (PC); non-Hodgkin lymphoma (nHL); Unclear—the number expressed do not match the actual sample analysed;
Not reported (NR).
Study Type of Drug Indication for Drug Therapy Time of Drug Exposure
Shimura et al. 2006 [41] MI MM × 1 32 months
Lee et al. 2007 [42] 2 × ALD OP × 2 1 in more than 108 months; 1 NR
Freiberger et al. 2007 [43]
2 ZOL +PAM
7 ZOL
6 BP (unknown)
1 PAM
BC × 3
MM × 10
Macroglobulinemia × 1
SC × 1
PC × 1
Unclear
Lee et al. 2011 [44]
ZOL × 3
ALD × 6
RES × 3
IBA × 1
OP × 7
MM × 1
PC × 3
nHL × 2
NR
Freiberger et al. 2012 [45] Unclear
OP (C-group × 5; S-group × 3);
MM (C-group × 9; S-group × 10);
BC (C-group × 7; S-group × 5);
Other indication (C-group × 6; S-group × 4)
Unclear
Fatema et al. 2015 [46] RES OP 24 months
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Table 9. HBO operative analysis including type of intervention and the stage of the disease. Platelet Rich Plasma (PRP); Standard of Care (StC); Antibiotics (ABX);
Mouthwash (MW); American Association of Oral and Maxillofacial Surgery (AAOMS); not applicable (N/A).
Study Type of Intervention Number of Cycles Pre-Operative Number of CyclesPost-Operative AAOMS Staging of Disease
Shimura et al. 2006 [41]
HBO + clarithromycin and
levofloxacin followed by
dexamethasone at 20 mg daily for
4 days.
N/A N/A Stage 2
Lee et al. 2007 [42] Sequestrectomy + PRP
No1 case 20 HBO at 2.4
atmospheres pressure for 90 min
The other case no HBO (due to
medical condition)
No 2 case NR
No1 10 HBO at the conclusion
of surgical treatment
The other case no HBO (due to
medical condition)
No 2 case NR
NR
Freiberger et al. 2007 [43]
11 × Debridement
1 × Resection
4 × just HBO
Unclear Unclear NR
Lee et al. 2011 [44] Unclear NR NR
Stage 0 × 4
Stage I × 1
Stage 2 × 5
Stage 3 × 3
Freiberger et al. 2012 [45]
StC (surgery + ABX + MW) × 21
(Control Group)
HBO + StC (surgery + ABX + MW)
× 25 (Study Group)
0 40 NR
Fatema et al. 2015 [46] Drug Holiday + ABX + surgery 20 10 Stage 2
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Table 10. HBO analysis of the MRONJ status at the end of follow-up; not reported (NR), poor patient compliance (PPC), computer tomography (CT). * RCT
Freiberger et al. 2012 [45] showed no statistically significant improvement in cure rate compared to placebo but there was improvement in secondary outcome.
Study Follow-up Time Type of Special InvestigationUsed during Patients’ Follow-up
Treatment Complications during
the Study
MRONJ Status after Treatment
at the End of Follow up
Shimura et al. 2006 [41] NR NR Patient developed acute otitis media(HBO interrupted and re-started) Stable
Lee et al. 2007 [42] 9 months CT × 1NR × 1 - Complete resolution
Freiberger et al. 2007 [43] From 1 to 32 months NR
PPC × 1
Multiple surgery × 2
HBO therapy more than one time × 4
Remission 8 (50%)
Stable 2 (12.5%)
Progression 6 (37.5)
Lee et al. 2011 [44] NR NR NR NR
Freiberger et al. 2012 [45] 24 months NR
Fatality × 3 (after 3 months);
HBO declined × 1;
Immediate Crossover to HBO Group × 2;
Late Crossover to HBO × 3
17 of 25 (68%) improved *
Fatema et al. 2015 [46] NR NR - Complete resolution
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7.3. OT Study Analysis
For OT, there were just 7 studies for analysis. Study types were described as case reports (n = 1)
and case series (n = 6). All these studies were published from 2006 to 2014 (Table 11).
Table 11. Studies included in the OT analysis, including number of patients treated and evidence
level. Case series (CS); Case report (CR); Levels of Evidence for Prognostic Studies Adapted from
the American Society of Plastic Surgeons (https://www.plasticsurgery.org/Documents/medical-
professionals/health-policy/evidence-practice/ASPS-Rating-Scale-March-2011.pdf).
Author(s) Type of Study Total Number of Patients Level of Evidence
Agrillo et al. 2006 [47] CS 30 Level 4
Agrillo et al. 2007 [48] CS 33 Level 4
Ripamonti et al. 2011 [49] CS 10 Level 4
Agrillo et al. 2012 [50] CS 131 Level 4
Ripamonti et al. 2012 [51] CS 24 Level 4
Brakus et al. 2013 [52] CR 1 Level 5
Brozoski et al. 2014 [53] CS 2 Level 4
A total of 231 patients were reported, 124 female (53.67%) and 74 male (32.03%), with 14.28% of
patients (n = 33) of unreported gender. Patients were treated using different OT protocols. The pooled
mean of age of these patients was 60.7 years. The most common indications for antiresorptive treatment
was multiple myeloma (35.93%), breast cancer (27.70%), prostate cancer (6.49%), lung cancer (6.49),
renal cancer (3.46%), uterine cancer (0.43%), non-Hodgkin lymphoma (0.43%) and osteoporosis with
lymphoma and thyroid cancer (4.76%). In a significant number of patients (14.28%), the drug therapy
indication was not reported (Tables 12 and 13).
The most common site for MRONJ was the mandible (43.72%), followed by the maxilla (22.94%).
In 8.65% of cases, MRONJ was reported in both, and the site was not reported in 24.67% of cases
(Table 12).
The drug most commonly responsible for MRONJ was Zoledronate (14.71%). However, only
37 patients out of 231 had details of the specific MRONJ-associated drug reported (16.01%). OT was
most commonly used as a neoadjuvant and/or adjuvant therapy, followed by surgery, in 6 studies out
of 7 (Table 14).
The patients were followed for a period of time ranging from 7 to 36 months. At the end of the
follow up, MRONJ was completely resolved in 44.58% of patients (n = 103), whilst 22.94% showed
some improvement or remission of the disease (n = 53). No progression of the disease has been
reported in any studies (Table 15); however, for 30 patients (12.98%), this data was not available.
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Table 12. OT Preoperative epidemiologic analysis (age, sex, predisposing factors, and site of the necrosis involved). Male (M); female (F); not reported (NR).
Study Age/Sex MRONJ Aetiology Site of Necrosis
Agrillo et al. 2006 [47] 10 M and 20 F, age ranging from 46 to79 years old (mean age was 63 years) Unclear
7 patients (23.3%) in the maxilla;
18 patients (60%) in the mandible;
5 patients presented with exposed
necrotic bone in both maxilla and mandible (16.7%).
Agrillo et al. 2007 [48] Unclear Unclear Unclear
Ripamonti et al. 2011 [49] 2 M and 8 F, age ranging from 53 to77 years old (mean age 65 years old)
8 patients after extraction; 2 from
prosthetic dentures 9 in the mandible and 1 in the maxilla
Agrillo et al. 2012 [50] 49 M and 82 F, age ranging from 38 and82 years old (mean age was 60 years old).
70 (52%) came after dental extraction with
exposure of necrotic bone in the same area.
36 (27.5%) spontaneous exposure of alveolar bone.
25 patients NR
43 patients (33%) in the maxilla;
73 patients (55.2%) in the mandible;
15 patients presented with exposed necrotic bone in
both maxilla and mandible (11.8%)
Ripamonti et al. 2012 [51]
12 M and 12 F,
age ranging 41–80 years old (mean age
62.5 years old)
NR NR
Brakus et al. 2013 [52] 1 F, 68-year-old Dental extraction Maxilla
Brozoski et al. 2014 [53] 1 M, 68-year-old; 1 F, 62-year-old 2 patients, dental extraction 1 Maxilla; 1 Mandible
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Table 13. Preoperative pharmacological analysis: type of drugs, indication for drug therapy and time
of drug exposure. Zoledronate acid (ZOL); Pamidornate (PAM); Alendronate (ALD); Risedronate (RES);
Osteoporosis (OP); Multiple Myeloma (MM); Breast Cancer (BC); Prostate Cancer (PC); * Unclear—the
number expressed do not match the actual sample analysed; Not reported (NR); Non-Hodgkin
Lymphoma (nHL); Lung Cancer (LC); Uterine Cancer (UC); Renal cancer (RC); Thyroid cancer (TC).
Study Type of Drug Indication for Drug Therapy Time of Drug Exposure
Agrillo et al.
2006 [47] NR
23 × MM
5 × BC
1 × UC
1 × PC
NR
Agrillo et al.
2007 [48] NR NR NR
Ripamonti et al.
2011 [49]
9 × ZOL
1 × PAM
6 × BC
2 × MM
1 × PC
1 × nHL
NR
Agrillo et al.
2012 [50] NR
56 × MM
41 × BC
11 × LC
8 × PC
8 × RC
7 × OP, Lymphoma and TC
NR
Ripamonti et al.
2012 [51] 24 × ZOL
11 × BC
4 × PC
4 × LC
3 × OP
2 × MM
Ranging from 10 to 18 months
Brakus et al.
2013 [52] PAM BC 42 months
Brozoski et al.
2014 [53]
1 × ZOL
1 × ALD + RES
1 × PC
1 × OP
21 months ZOL; 48 months ALD
+ 24 months RES.
Table 14. Ozone therapy (OT) operative analysis including type of intervention and the stage of the
disease. Spontaneous expulsion of necrotic bone (SENB); antibiotics (ABX); American Association of
Oral and Maxillofacial Surgery (AAOMS); not reported (NR).
Study Type of Intervention Number of CyclesPre-Operative
Number of Cycles
Post-Operative
AAOMS Staging of
Disease
Agrillo et al.
2006 [47]
Surgical debridement +
ABX Unclear Unclear Stage 1
Agrillo et al.
2007 [48] Surgical debridement
1 (8 session of 3 min);
OT + ABX + antifungal
1 (8 session of 3 min);
OT + ABX + antifungal
+ Vitamin C
NR
Ripamonti et al.
2011 [49]
ABX + ultrasonic
scaling
3 to10 applications of
OT oil (mean
applications were 5.5)
None
NR
(Weitzman et al. 2007
staging utilised)
Agrillo et al.
2012 [50]
Curettage or
sequestrectomy None Unclear NR
Ripamonti et al.
2012 [51]
ABX followed by
SENB and/or
sequestrectomy
3 to 38 applications of
OT gas (mean
applications were 11)
None No AAOMS used(Weitzman et al. 2007)
Brakus et al.
2013 [52]
Debridement + ABX
(initially); eventually
radical surgery
7 applications None Stage 2
Brozoski et al.
2014 [53]
Mouthwash + Surgical
debridement Unclear None
Stage 2 × 1
Stage NR × 1
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Table 15. OT analysis of the MRONJ status at the end of follow-up. Orthopantomograph (OPG); not reported (NR).
Study Follow-up Time
Type of Special Investigation
Used during Patient’s
Follow-Up
Treatment Complications
during the Study MRONJ Status after Treatment at the End of Follow-Up
Agrillo et al. 2006 [47] NR NR NR NR
Agrillo et al. 2007 [48] 7 months NR NR
18 patients (54%) completed healing of the lesion;
10 patients (30%) experienced reduction of the lesion
dimension;
5 patients (16%) showed no clinically relevant improvement
outcomes on the lesion.
Ripamonti et al. 2011 [49] 8 months NR None All patients have shown sign of healing of the lesion.
Agrillo et al. 2012 [50] Unclear NR 37 patients withdrawn from theresearch
57 patients had complete resolution (60%); 28 patients had
reduction of the dimension of lesions (30%);
9 patients (10%) showed no clinically relevant improvement
outcomes on the lesion.
Ripamonti et al. 2012 [51] Range 12 to 36 months(mean 18 months) NR
7 patients interrupted the
treatment with OT for disease
progression and 1 for fear of an
experimental therapy.
16 patients have shown complete resolution of the MRONJ.
Brakus et al. 2013 [52] Unclear Unclear None Reduction of the dimension of lesions.
Brozoski et al. 2014 [53] 36 months × 118 months × 1 OPG None Complete resolution.
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8. Risk of Bias and Review Quality Assessment
In all three case report studies, we identified a lack of clarity in many of the thirteen domains of
the CARE Checklist, with missing information. We found that the lack of clarity was predominantly
on follow-up and diagnostic procedures at the time of follow-up. Hence, we concluded the level
of bias to be high for all the included case reports. In the nine case series studies, we reported a
consistent lack of clarity in some of the seven domains of the Modified Delphi Checklist. These were
predominantly regarding the outcome measurement methods, hence we considered the level of bias to
be high for all case series studies. The only eligible RCT was an evaluation of adjuvant HBO therapy for
people undergoing surgery. The authors of the study did not mention the generation of randomisation
sequences but reported the concealment of allocation using a series of opaque envelopes containing
the assignment, and we therefore rated the level of risk as unclear. The personnel involved in the study
were not blinded because this was deemed to be impractical. The loss of patients to follow-up was
substantial, and although a clear description of losses and withdrawals was given, data analysis was
performed as-treated. Moreover, the study had a very high and unbalanced rate of crossovers between
study arms. Therefore, we considered the level of risk of bias to be high across the study [41–53].
9. Discussion
Antiresorptive drugs are known to improve the quality of life for patients affected by bone
metastasis, osteoporosis, osteopenia and Paget disease. Moreover, the new antiangiogenic drugs have
been shown to be effective treatment modalities for a number of cancers. Unfortunately, increased
use of these drugs has also increased the numbers of patients developing MRONJ. The risk appears
to be highest in patients who require intravenous drug administration or an intake period greater
than two years [12,54,55]. Moreover, the literature suggests that local and systemic factors (such as
periodontal disease and diabetes) might act as predisposing factors in developing MRONJ. Although
no gold standard is currently available for the treatment of MRONJ, a number of studies debate which
MRONJ stage benefits the most from surgical or conservative therapy [15,56]. In general, the common
opinion appears to be that for early stages of the disease (stage 0 or I), conservative management might
be sufficient [6,54].
The purpose of this systematic review was to analyse the current evidence related to the treatment
of MRONJ when using oxygen therapy (OT and HBO). Our findings indicate that the oxygen therapy
has been used as a neoadjuvant or adjuvant therapy and may represent a viable complementary
treatment or an alternative in advanced stage disease (stage II and III) where patients are unfit for
aggressive surgery such as jaw resections or microvascular reconstruction. Despite the majority of
studies reviewed presenting low quality evidence with a high risk of bias, there is some evidence
to show the total resolution of MRONJ in 44.58% of patients with OT and 5.17% of patients with
HBO, although this could equally have happened without these interventions. In addition, in a
number of OT studies, the spontaneous sequestration of necrotic bone was followed by a spontaneous
expulsion [47–53]. The only reported cases of MRONJ progression were amongst patients treated with
HBO (10.34%, n = 6). Unfortunately, these outcomes were not reported for 13.73% (n = 43), which
could represent further cases of disease progression.
This review also found that in the majority of the MRONJ cases, antiresorptive drugs were
explicitly discontinued if deemed safe from the oncological point of view [41–53]. However, it is
unclear if the discontinuation strategy leads to a better surgical outcome due to the long skeletal life of
some antiresorptive drugs.
Amongst all the studies, we have found several perplexities which have had an impact in the
quality of the research. Indeed, we have noticed that in 11 articles out of 13, there was no mention of
any specific investigations during the patients follow up. Only Lee et al. [42] and Brozoski et al. [53]
have reported, during the follow up, that patients had either a CT or an orthopantomograph (OPG) to
assess the radiological aspect of the MRONJ lesions. Moreover, other important data were missing
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in many of the articles, such as cumulative drug dose prior to developing MRONJ and patients’
predisposing factors such as other medical conditions and dental history.
Only one article utilised a QoL questionnaire to assess baseline and post treatment levels at six
months. The questionnaire evaluates six health domains (physical, mental, social, general, perceived
health and self-esteem) and four dysfunction measurements (anxiety, depression, pain and disability),
reporting no statistically significant differences between the two groups [45].
It is understandable that due to the limited incidence of MRONJ, it is difficult to improve
the quality of evidence unless a common effort is applied. Therefore, the authors believe that
additional high-level-evidence studies, such as multi-centre studies, case-controlled studies or
randomised controlled trials, are necessary to support the efficacy and the success of oxygen therapy
in managing MRONJ.
The authors advocate, in general, that the following rules should be applied for MRONJ treatment
research protocols:
• Diagnosis and staging of the disease should be assessed with standardised reproducible scales
and should be calibrated amongst the clinicians involved in the study.
• If randomisation is feasible, it should be carried out and described in sufficient detail to allow an
assessment of whether it produced comparable groups.
• Common, quantifiable and clinically relevant endpoints (time to complete wound healing, pain,
specific investigations, treatment acceptability and participant satisfaction) should be described
in a sufficiently detailed manner.
• A long follow-up period of at least six months is essential if treatment effects on indolent, often
long-standing MRONJ sites, are to be detected.
10. Conclusions
MRONJ is becoming an increasingly significant iatrogenic complication for patients undergoing
antiresorptive and antiangiogenic drug therapy as these important medications reduce the morbidity
and mortality rates associated with the primary disease. Unfortunately, the management of MRONJ
remains controversial. This is the first systematic review of oxygen therapy for the management of
MRONJ and highlights the absence of high-level evidence in the literature. Therefore, it is currently
difficult to suggest OT is better or worse than HBO, or whether it is better than a placebo. In the
absence of effective MRONJ treatment strategies, the available data does however suggest that further
well-designed clinical studies are warranted to improve the evidence base for both OT and HBO in the
management of MRONJ.
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